Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 0.85 |
| ▸ | FPGS | Q05932 | 2/20 | 0.84 |
| ▸ | GART | P22102 | 5/20 | 0.64 |
| ▸ | DHFR | P00374 | 1/20 | 0.58 |
| ▸ | ATIC | P31939 | 4/20 | 0.56 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20509041 | 1.00 | SOST (0.85) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL27903149 | 1.00 | SOST (0.85) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL7077904 | 1.00 | SOST (0.85) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL133543 | 1.00 | SOST (0.85) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL28206347 | 0.99 | SOST (0.84) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL27284124 | 0.99 | SOST (0.84) | SOSTFPGSGARTDHFRATIC | |
| Phosphoric Acid SCHEMBL28313723 | 0.98 | SOST (0.82) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL27798266 | 0.98 | SOST (0.90) | SOSTFPGSGARTDHFRATIC | |
| Glycine SCHEMBL27746532 | 0.97 | SOST (0.83) | SOSTFPGSGARTDHFRATIC | |
| Butyric Acid SCHEMBL28187742 | 0.94 | SOST (0.76) | SOSTFPGSGARTDHFRATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030148991-A1 | Use of at least one lipoic acid, of a physiologically acceptable derivative and/or salt thereof and at least one C1 donor for producing formulation for C1 donor-assisted therapy of central nervous system disorders | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148991-A1 | Use of at least one lipoic acid, of a physiologically acceptable derivative and/or salt thereof and at least one C1 donor for producing formulation for C1 donor-assisted therapy of central nervous system disorders | AMD1, MAT1A, C1S | SOST 3540/4885FPGS 259/4885GART 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.